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Despite the rapid expansion in recent years of databases reporting either benign or pathogenic 
genetic variation, the interpretation of novel missense variants can remain challenging, 
particularly for clinical or genetic testing laboratories where functional analysis is often 
unfeasible. Previous studies have shown that thermodynamic analysis of protein structure in 
silico can discriminate between groups of benign and pathogenic missense variants. 
However, although structures exist for many human disease-associated proteins, such 
analysis remains largely unexploited in clinical laboratories. Here, we analysed the predicted 
effect of 338 known missense variants on the structure of menin, the MEN1 gene product. 
Results provided strong discrimination between pathogenic and benign variants, with a 
threshold of >4 kcal/mol for the predicted change in stability providing a strong indicator of 
pathogenicity. Subsequent analysis of 7 novel missense variants identified during clinical 
testing of MEN1 patients showed that all 7 were predicted to destabilise menin by >4 
kcal/mol. We conclude that structural analysis provides a useful tool in understanding the 
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impact of missense variants in MEN1, and that integration of proteomic with genomic data 
could potentially contribute to the classification of novel variants in this disease. 
INTRODUCTION  
The rapid expansion in recent years of genomic data from both patient and control groups has 
vastly improved the quantity and quality of information that is available to clinicians in 
attempting to classify novel genetic variants. While it is often straightforward to interpret 
likely loss-of-function variants such as stop-gain or frameshift variants, the same is not true 
of missense variants, where the effect of an amino acid substitution is likely to be specific to 
its context in the protein of interest. Moreover, such variants are often rare or unique, and 
thus must be interpreted on a case-by-case basis. 
Numerous methods have been developed for predicting the phenotypic effect of missense 
variants. As has been comprehensively reviewed elsewhere (1), these methods rely either on 
analysis of DNA and protein conservation, protein structure-based analysis, or a combination 
of the two. In the case of the latter, widely used tools such as PolyPhen are able to 
incorporate information on the nature of the amino acid change itself (e.g. Grantham distance 
between native and variant amino acids, changes in polarity or charge), effects on predicted 
secondary structure and, where available, data derived from the structural context, such as 
changes in hydrogen bonding or atomic crowding. However, such data is used in a 
qualitative, rule-based manner in the final prediction (1), and the tools which are most widely 
used in the clinical setting do not specifically address the quantitative effects of missense 
variants on protein stability. Nevertheless, these effects can be calculated where there is an 
experimental or modeled 3D structure for the protein of interest, and programs such as FoldX 
(2), Rosetta (3, 4) or other computational methods have been widely used by structural 
biologists to investigate the effects of missense variants on protein folding and stability (5, 6). 
Despite this, few studies have sought to address whether there is a direct clinical application 
of such an approach, i.e. whether pathogenic and benign variants can be distinguished on the 
basis of their predicted effects on thermodynamic stability.  
The potential utility of protein stability data towards the analysis of missense variants has 
recently been demonstrated in studies of the Lynch syndrome protein, MSH2 (7), and in 
phenylalanine hydroxylase (PAH) (8), in which pathogenic variants result in phenylketonuria. 
Both these studies combined in silico analysis with extensive functional analysis of a number 
of MSH2 and PAH variants; however, resources for the latter are unlikely to be routinely 
available in clinical genetics laboratories. We have therefore asked whether in silico analysis, 
based predominantly on the predicted effects of missense variants on protein stability, can 
help discriminate between pathogenic and benign variation in the context of clinical testing of 
the MEN1 gene. 
Pathogenic variants in the MEN1 gene cause Multiple Endocrine Neoplasia type I, an 
autosomal dominant disorder, in which patients develop neoplastic lesions in various 
endocrine tissues, principally the parathyroids, pituitary and pancreas (9). Pathogenic variants 
may either be inherited or acquired, but in both cases development of disease requires loss of 
heterozygosity consistent with a role for menin, the MEN1 gene product, as a tumor 
suppressor. The biological activity of menin is not fully understood, but it is known to bind to 
and inhibit the activity of JunD (10), a component of the proliferation-associated transcription 
factor AP-1. Loss of menin activity is presumed to result in deregulated activity of AP-1, 
leading to increased cell proliferation and ultimately neoplasia. Menin also regulates gene 
expression via interaction with the histone methyltransferase KMT2A (MLL1), and forms an 
essential component of the MLL complex which upregulates expression from target genes 
including those of the HOX cluster (11). Menin may also play a role in DNA damage repair 
via an interaction with FANCD2, and loss of activity has been shown to result in increased 
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sensitivity to DNA damage (12). Finally, menin has been shown to repress telomerase 
activity, and depletion of menin in human fibroblasts results in their immortalization (13). 
Potentially therefore there are a number of pathways by which loss of menin activity could 
lead to neoplasia and tumor formation. 
The most common presenting feature of MEN1 is hyperparathyroidism, which occurs in 
~95% of patients due to tumors of the parathyroid gland; however, tumors are also frequently 
observed in the pancreatic islets (40-70%) and pituitary (30-40%) (14). Patients may also 
develop tumors of the adrenal cortex, carcinoid tumors and non-endocrine tumors, including 
lipomas, angiofibromas, collagenomas and meningiomas (15), resulting in a range of clinical 
symptoms which may overlap with other diseases of different genetic etiology (16-18). This 
overlap presents one of the key problems in assessing genetic variants in cases of MEN1. 
While a large number of pathogenic variants in MEN1 have been reported, genetic testing 
continues to uncover novel missense substitutions which require assessment of their potential 
pathogenicity. A further confounding issue is the often later onset of disease, with reported 
age-related penetrance of 10-43% at 20 years and 81- 94% by 50 years (14, 19), which may 
lead to apparent non-segregation of a variant with disease within a family pedigree.  
The identification of a genetic etiology has important implications for the patient and for 
their family members. With the exception of pituitary neuroendocrine tumors, MEN1-
associated tumors are usually multiple and treatment is therefore challenging, requiring a 
multi-disciplinary team of experts to reduce morbidity and mortality (20). The identification 
of the familial disease-causing variant enables the identification of carriers when they are still 
asymptomatic. Clinical surveillance in these individuals allows early recognition of the 
clinical manifestations and therapeutic intervention. For example, primary 
hyperparathyroidism often remains asymptomatic in many patients but prolonged 
hypercalcemia usually results in bone loss and/or nephrocalcinosis (21). 
Approximately 20% of the variants identified in the MEN1 gene are missense variants 
(22). The standards and guidelines published by the American College of Medical Genetics 
and Genomics (ACMG) and the Association for Molecular Pathology (AMP) describe a 
framework for the classification of sequence variants (23). Adjustments to this framework for 
the interpretation of MEN1 missense variants has been proposed (24). However both agree 
that variants of uncertain significance should not be used to guide the clinical management of 
patients. This could lead to an under-diagnosis of MEN1 and a lost opportunity for screening 
at-risk relatives. For these reasons, methods to assist the classification of variants in MEN1 
would be of clinical value. The availability of a number of experimental structures for menin, 
the MEN1 gene product, raises the possibility that structural analysis may provide such 
clinical utility.  
We report here that thermodynamic analysis of MEN1 variants in silico provides a very 
strong positive predictive value for pathogenicity, thereby helping to assess the impact of 
novel missense variants on protein function and potentially allowing its use as an aid to 
variant classification, and discuss briefly the scope for wider application of this approach to 
other diseases. 
MATERIALS & METHODS 
Variant groups, transcripts and numbering.  
Lists of previously-reported, inherited missense SNVs in MEN1 were downloaded from the 
Human Gene Mutation Database, Professional version (HGMD Pro) (25), the Genome 
Aggregation Database (gnomAD) (26) and the Sydney Genomics Collaborative Database 
(SGCD) (27). For the purposes of this analysis, variants were divided into groups as follows: 
pathogenic: DM (‘disease mutation’) class variants reported in HGMD Pro but not in 
gnomAD or SGCD (n=162); benign: variants reported in gnomAD or SGCD but not as DM 
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class in HGMD Pro (n=206); uncertain: variants reported as DM in HGMD Pro and present 
in gnomAD and/or SGCD (n=14). Different nucleotide substitutions resulting in the same 
coding change were regarded as a single missense substitution. In addition to these 
previously-reported variants, analysis was performed on seven novel missense variants: 
H46P; A164P; L175P; A345P; I360F; F364S; and G419D (see Table 1 for details). These 
variants were identified in our laboratory as part of the NHS (England) Genetic Testing 
service for rare inherited diseases. The patients tested fulfilled the criteria for a clinical 
diagnosis of MEN1 (14), presenting with at least two out of the three main MEN1-associated 
endocrine lesions or one typical MEN1-associated tumour and a first-degree relative with 
MEN1 or MEN1-associated lesion at a young age. For patients with a family history, the 
relevant variants (H46P, A164P, I360F and F364S) were all shown to co-segregate with 
disease in the family. Informed consent for genetic testing was obtained from all subjects. 
There is one major isoform (610 amino acids) and one minor isoform (615 amino acids) 
of menin in the sequence databases. The longer minor isoform could have originated by use 
of an alternative splice donor site in exon 1 such that the longer isoform contains 5 residues 
inserted at the end of exon 1 (at amino acid 148) that leads to a total 615 amino acid coding 
region. While gnomAD and SGCD variants are annotated according to the 615-residue 
isoform encoded by transcripts NM_130803/ENST00000337652, HGMD Pro and structural 
databases use the 610-residue isoform encoded by NM_130799/ENST00000312049 as 
default. All numbering in this manuscript refers to the 610-residue form of menin, and 
variants from gnomAD and SGCD have been re-annotated accordingly.  
Protein structures.  
Structures of human menin were downloaded as PDB files from the worldwide Protein Data 
Bank (28); a full list of the 29 crystal structures, containing 31 discrete menin chains, used in 
this analysis is shown in Table 2. Any non-native amino acids (e.g. affinity purification tags) 
in these structures were removed from PDB files prior to further analysis.  
In silico mutagenesis and thermodynamic analysis.  
Prior to in silico mutagenesis, sidechain repair and energy minimization was performed on all 
31 menin chains in isolation, using the RepairPDB function of the FoldX modeling suite (2), 
version 4. The FoldX BuildModel function was then used to introduce individual 
substitutions into each of the repaired PDB structures. Of the 389 unique missense variants, 
338 were covered by at least one PDB structure (pathogenic, n=161; benign, n=161; 
uncertain, n=9; novel, n=7). For each substitution, FoldX reported a change in free energy 
(∆∆G) resulting from the substitution; from this, an average ∆∆G value was calculated for 
each variant across all structures containing the relevant position. In total, all 31 structures 
were used for 308/338 variants (mean for all variants = 29), whereas due to differences in 
coverage of individual PDB files, analysis was possible using only a single structure for 7 
variants. A full list of variants, the number of PDB structures analysed for each and average 
∆∆G values for each variant has been published online (37). All structures were visualized in 
PyMOL (38). 
Calculation of solvent accessibility.  
The absolute area accessible to solvent (ASA) was calculated on a residue-by-residue basis 
for 7 representative structures of menin using DSSP (39, 40) version 3.0.0 (41). After 
calculating an average ASA value for each residue, relative solvent accessibility (RSA) was 
derived using the theoretical scale described by Tien et al. (42). A list of structures used for 
DSSP analysis is included in Table 2.  
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RESULTS 
 Pathogenic variants in MEN1 are predicted to be more destabilising than benign variants.  
Over 30 crystal structures have previously been reported for menin (e.g. Figure 1A); most of 
these contain the protein in isolation or bound to a small (drug) ligand, while others show 
menin in complex with peptides from JunD, KMT2A or PSIP (Figure 1B; Table 2). Although 
all structures have been derived from expression of full-length (or near full-length) menin, a 
number of regions remain unresolved in crystal structures. These regions predominantly lie in 
the C-terminal of the protein and correspond to stretches of predicted intrinsic disorder (43) 
in the protein (Figure 1C, D), presumably resulting in high mobility within crystals. 
Interestingly, while these regions contain a similar distribution of benign variants as that seen 
in the protein as a whole, inherited pathogenic variants are rare in regions of predicted 
disorder in menin (Figure 1D); however, we cannot rule out the possibility that the lack of 
pathogenic variants in these regions is due to reporting bias towards variants which lie close 
to those already known. Furthermore, recurrent missense variants have been observed in 
disordered regions of menin in the COSMIC database of somatic mutations in cancer (44), of 
which three (R479W, R485Q and P540R) have not been reported in gnomAD. It is possible 
therefore that missense variants in disordered regions play a role in pathogenicity, 
particularly when arising as somatic mutations. With respect to inherited pathogenic variants 
however, their distribution almost entirely within ordered regions means that the vast 
majority (161/162) are covered by one or more PDB entries and are thus amenable to 
structural analysis. 
The overall structure of menin is highly comparable within all reported PDB structures 
(alignment to PDB 6b41 yields an average root-mean-square deviation, RMSD, of 0.65 Å; 
range 0.55-1.10 Å). Moreover, there is no significant effect of ligand binding on menin 
structure (Figure 2). Since different PDB files contain slightly different numbers of amino 
acids but there are no obvious structural outliers, all available structures were used for 
thermodynamic analysis of missense variants in silico using FoldX.  
Benign and pathogenic variant groups were highly distinguishable by their predicted 
effect on thermodynamic stability, as represented by average ∆∆G value calculated across all 
structures. Variants resulting in ∆∆G >3 kcal/mol are generally regarded strongly 
destabilising (45). The average ∆∆G value for all pathogenic variants was 5.06 kcal/mol (SD, 
4.25 kcal/mol), with 108/161 of these (67.1%) predicted to be strongly destabilizing (∆∆G 
>3kcal/mol). In contrast, the average ∆∆G value for putatively benign (gnomAD and SGCD) 
variants was 1.13 kcal/mol (SD, 1.46 kcal/mol), with only 17/161 (10.6%) having an effect in 
excess of 3 kcal/mol (Figure 3A). Notably, all seven novel missense variants were also 
predicted to be strongly destabilising (average ∆∆G, 7.67 kcal/mol; SD 3.14 kcal/mol; range, 
4.81-13.16 kcal/mol). Analysis of ∆∆G values for individual PDB structures showed a similar 
separation of putative benign and pathogenic variant groups, with the vast majority of 
variants falling into a similar range for all structures (Figure 3B). We further compared the 
effect at multi-allelic sites where different benign and pathogenic missense variants occur at 
the same position. Analysis of 27 benign and 23 pathogenic variants co-occurring at 22 
residues again showed that the difference between the two groups was highly significant (p = 
0.0002), and that as a group, pathogenic missense changes were more strongly destabilizing 
than benign ones at the same position (average ∆∆G value by group = 6.81 kcal/mol and 2.18 
kcal/mol respectively) (Figure 3C). Therefore since both pathogenic and benign variation can 
occur at the same site within menin, it is important to consider both the position and nature of 
the amino acid change; this data suggests that ∆∆G value may provide a useful tool in 
assessing the impact of novel variants at multi-allelic sites.  
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If variants which destabilize menin structure do indeed have a greater tendency to be 
pathogenic, it might be expected that variants most frequently observed in the general 
population would have the least destabilizing effect. This appears to be the case, as variants 
with the highest population frequency had average predicted ∆∆G values in the range -1 to +1 
(Figure 4); as the error in FoldX calculations is approximately ±0.8 kcal/mol (2), this 
suggests little or no effect of these variants on protein stability. Notably, those variants which 
have also been observed in an aging healthy population, as represented by the SGCD cohort 
(median age, 80-85 years) and are therefore most likely to be truly benign, all occur within 
this range of ∆∆G values. This group includes the only commonly-occurring missense MEN1 
variant, R171Q, which has an average ∆∆G value of 0.15 kcal/mol. Conversely, we note that 
some variants reported in gnomAD have ∆∆G values >4 kcal/mol, and in fact 2/9 of these 
variants (S38P, D315Y) have also been reported as disease-causing in HGMD Pro. This may 
reflect the confounding effect of late onset of symptoms in MEN1 on apparent constraint 
against coding variation, whereby some variants reported in gnomAD may in fact lead to 
disease in later life. 
Most pathogenic variants are buried in the menin structure.  
To examine whether there are differences in the spatial distribution of benign and pathogenic 
variants, we calculated the relative solvent accessibility (RSA) of wild-type residues at all 
positions of missense substitutions (37). This showed that while positions of benign variants 
are distributed throughout the volume of the protein, 86.3% of pathogenic variants occur in 
solvent-inaccessible (i.e. buried) regions of RSA <0.2 (Figure 5A). Notably, this is also true 
for the 7 novel variants, 6 of which had an RSA value <0.02. Plotting RSA against ∆∆G 
showed that variants at buried positions were also likely to be the most strongly destabilizing 
to protein structure (Figure 5B). Nevertheless, we observed that a significant number of 
pathogenic variants exhibited both accessibility to solvent (RSA>0.2) and relatively low 
∆∆G. Mapping the positions of solvent-accessible variants onto the surface of menin showed 
that, as for distribution throughout the internal volume of the protein, benign variants tended 
to be distributed across the surface. In contrast, pathogenic variants appeared to occur in 
clusters, one of which corresponds to binding surfaces for JunD, KMT2A and PSIP (Figure 
5C, D), while another occurs on the opposite surface of menin to the JunD binding pocket. It 
is possible therefore that the latter region represents the site of an as-yet uncharacterized 
functional interaction of menin. As described above, 6/7 novel missense variants occur at 
positions which are buried in the interior of the protein, whereas the only solvent-accessible 
variant, H46P, occurs at the interface with KMT2A and presumably acts to impair this 
interaction (Figure 5E).  
To investigate the effects of protein interactions on the thermodynamic effects of MEN1 
variants further, we compared ∆∆G values for variants in PDB structure 3u88 (menin 
complexed with KMT2A and PSIP peptides) by analysis both of menin chains in isolation 
(chains A, B) and complexed to KMT2A and PSIP. As expected, regions of decreased 
solvent accessibility in the complexes aligned with residues annotated as forming protein-
protein contacts (Figure 6). However, the presence of bound peptides had little effect on ∆∆G 
values of benign variants, indicating that these have a neutral effect on protein binding. 
Conversely, protein binding had a large effect on ∆∆G values of a number of pathogenic 
variants; again, these predominantly occurred at or close to protein interfaces, indicating that 
these variants are likely to have a direct effect on ligand binding by menin. 
Destabilizing variants reduce levels of functional menin protein.  
Previous reports studying the effects of missense variants on levels of functional menin 
within the cell have shown that pathogenic variants have a tendency to increase protein 
turnover and/or reduce the steady-state level of protein, while benign variants tend to have no 
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such effect (46, 47). We correlated the previously-reported effects of variants on levels of 
steady-state protein with average ∆∆G values, and observed that variants which were 
predicted to be strongly destabilizing in silico (∆∆G >3 kcal/mol) exhibited significantly 
lower levels of steady-state protein in cell-based assays (p=0.0001, Figure 7), consistent with 
the hypothesis that variants with high ∆∆G values reduce the biological activity of menin. 
Can ∆∆G value be used as an aid to variant classification?  
To evaluate the clinical validity of ∆∆G values, we performed Receiver Operating 
Characteristic (ROC) curve analysis for the groups of benign and pathogenic variants and 
compared the results with the outputs from a number of commonly-used phenotypic 
predictions tools: SIFT (48), PolyPhen (49) and REVEL (50). All methods yielded areas 
under the curve (AUC) of 0.819-0.864, indicating that all have clinical validity (Figure 8A). 
However ∆∆G analysis resulted in the highest specificity but lowest sensitivity. Values of 
∆∆G > 3 kcal/mol are generally regarded as being strongly destabilizing towards protein 
structure (45); taking this as a threshold for variant classification gives sensitivity and 
specificity of 67.1% and 89.4% (positive predictive value, 86.4%), while setting a more 
conservative threshold of ≥4 kcal/mol increased the specificity to 95.0%, though with a 
concomitant loss of sensitivity (54.0%; positive predictive value, 90.6%). A marginal 
increase in positive predictive value (PPV) could be obtained by combining ∆∆G thresholds 
with a cut-off in the REVEL score of 0.7, which has been reported to exclude 95% of false 
positive calls (51), yielding PPV’s of 87.7% at ∆∆G ≥ 3 kcal/mol and 91.5% at ∆∆G ≥ 4 
kcal/mol. Notably, all seven novel missense variants reported here cluster within the upper 
right quadrant (Figure 8B), consistent with a severe impact on protein stability and suggesting 
that ∆∆G values can potentially be used to provide evidence towards variant classification in 
MEN1. 
DISCUSSION 
Previous work has shown that predicted thermodynamic destabilization of protein structure, 
as measured by ∆∆G values calculated by FoldX, can be used as a predictor of pathogenicity 
in MSH2 and PAH variants (7, 8). Our data indicates that the same is true for variants in 
MEN1, and that a high predicted ∆∆G value is a strong positive predictor for pathogenicity. 
Using a threshold value of ∆∆G >3 kcal/mol, which is generally regarded as strongly 
destabilizing, yielded a specificity of 89.4% for classification of menin variants, rising to 
95.0% for a more conservative threshold of 4 kcal/mol. By contrast, using a proposed 
threshold of 0.7 for the phenotypic meta-prediction tool REVEL yielded a specificity of only 
53%. Although MEN1 has a high degree of penetrance, with more than 95% expected to 
develop symptoms by the sixth decade of life (9), there appears to be no correlation between 
MEN1 variants and clinical manifestations, with inter- and intra-familial variation observed 
(22). Therefore the identification of likely pathogenic variants has significant implications for 
patient surveillance and genetic testing of family members. For example, analysis of a large 
cohort of Florentine patients showed age at genetic diagnosis for relatives of the index cases 
as 31.2 + 16.9 years, with a range of 1–71 years (21). With respect to the seven novel 
missense variants reported here, all had high average predicted ∆∆G values (range, 4.81-
13.16 kcal/mol) and six were deeply buried within the protein, strongly supporting 
pathogenicity. All these cases were also predicted as deleterious or probably pathogenic by 
commonly-used tools for in silico pathogenicity prediction; however, the comparatively low 
specificity of all these tools for variants in MEN1 highlights the value of thermodynamic 
analysis as a means of reducing false positive calls. 
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As might be expected, our analysis shows that variants which are buried within the menin 
structure are those that are predicted to result in greatest structural destabilization. In fact, the 
majority (86.3%) of reported germline pathogenic variants in MEN1 are buried, suggesting 
that any novel variant which is solvent inaccessible (RSA<0.2) and has a predicted ∆∆G >4 
kcal/mol is also highly likely to be pathogenic. Nevertheless, a number of pathogenic variants 
lie on the surface of menin, and many of these have relatively low ∆∆G values. A number of 
these variants lie at or close to positions of known interactions with binding partners such as 
JunD, KMT2A or PSIP, where they presumably have an adverse effect on binding of these 
factors, emphasizing the value of integrating all known structural annotation into a final 
classification of the likely effect of a variant. Our data also suggests the possible existence of 
an as-yet unidentified interaction of menin, as evidenced by the cluster of pathogenic variants 
lying on the protein surface opposite the JunD binding pocket. Interestingly, in a recent 
analysis of the spatial distribution of missense variants (52), MEN1 was identified as one of a 
group of genes displaying significant spatial clustering of pathogenic and likely pathogenic 
missense variants in the ClinVar database (53), but not of benign or likely benign missense 
variants reported in gnomAD. Inspection of ClinVar (accessed 19 September 2019) revealed 
that of 346 missense variants in MEN1, only 50 unique variants (excluding start-loss variants) 
were classified as pathogenic or likely pathogenic, with a large majority (276) classed as 
being of uncertain significance. Although we have used a different database, HGMD Pro, as 
the source for our dataset of ‘pathogenic’ variants, there is considerable overlap between the 
two, with 39/50 (78%) of the pathogenic or likely pathogenic ClinVar variants also being 
present in our dataset, while a further 27 variants in our dataset were colocalized with a 
ClinVar variant. However, the discrepancy between the total number of ‘pathogenic’ variants 
in the two datasets highlights the need for more reliable tools for classification of variants in 
MEN1. 
In terms of broader applicability of this approach, our work builds upon the reported 
analysis of MSH2 and PAH variants and applies it to the classification of novel clinical 
variants. Whether the same approach can be used for other proteins remains to be determined. 
One obvious limitation of structural analysis is, by definition, the need for a suitable 
structural model. However, even where no experimental structures are available for a protein 
of interest, it may still be possible to use comparative modelling to generate a reliable model 
of regions or domains which can be used for structural analysis. Another likely limitation is 
the architecture of the protein itself. Both menin and MSH2 are relatively compact, globular 
proteins, with low surface area to volume ratio and a high proportion of amino acids in 
regions of secondary structure. As a result, the effect of missense variants on the internal 
geometry and thermodynamic stability of the proteins is amenable to in silico prediction, 
particularly given the availability of suitable high-quality PDB structures. It seems likely 
therefore that the approach used here may have broader applicability in proteins which 
contain a high proportion of buried residues in regions of strong secondary structure; indeed, 
the potential for wider use of in silico thermodynamic analysis of protein stability as part of a 
pipeline for assessing the impact of missense variants has recently been reviewed (54). 
However, less well-structured proteins, or fibrillar proteins where a greater proportion of 
amino acids are exposed to solvent, are likely to be less amenable to such study as the 
confidence with which the structural and thermodynamic effects of missense variants can be 
predicted will be greatly reduced. Such rules are likely to be revealed only by proteome-wide 
study which is beyond the scope of this manuscript. 
In summary, we have shown that structural analysis of missense substitutions in MEN1 
can be used to identify variants likely to destabilize the protein and thus potentially as an aid 
in variant classification. Given that all analysis described herein used publicly-available data, 
freely-available software and does not require specialist bioinformatic skills or infrastructure, 
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such analysis lies within the capability of any genetics laboratory or testing service. As such, 
there is significant scope to make greater use of protein structural data in the routine 
interpretation of genetic variation. 
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Figure 1: Structure and disorder in menin. A) The structure of menin, as represented by 
PDB entry 3u88 chain A; protein surface is coloured from blue, N-terminal to red, C-
terminal; the position of the binding pocket for JunD and KMT2A is indicated; numbered 
residues coloured magenta indicate positions flanking disordered loops which are not 
resolved in the crystal structure. B) menin (grey) in complex with KMT2A (yellow) and PSIP 
(green), as determined in PDB 3u88; note that while one end of KMT2A occupies the binding 
pocket, interaction with PSIP and other regions of KMT2A extends over a wider region of the 
menin surface. C) Probability of intrinsic disorder in menin, as calculated by the 
MetaDisorder predictor, plotted against amino acid position; extended regions of probability 
>0.5 are considered to be disordered. D) Coverage of menin residues in the 31 PDB 
structures used in this analysis, aligned against amino acid position as in part C. The top line 
shows coverage in PDB 3u88A, coloured as in 1A; numbering indicates residues flanking 
unstructured regions missing from the crystal structure. Below this, black horizontal lines 
show coverage for the 30 remaining PDB structures, while positions of benign and 
pathogenic variants are indicated by blue or red triangles indicate respectively. Note that 
regions of predicted intrinsic disorder are absent from the majority, if not all crystal 
structures, consistent with greater mobility of these residues within the crystal, and that few 
pathogenic variants have been reported in these regions. 
Figure 2: Alignment of menin structures. A) The α carbon atoms of the 31 menin 
structures used in this study were aligned to that of PDB 6b41; each chain is shown in ribbon 
format, coloured by PDB and chain identifier; the position of the JunD/KMT2A binding 
pocket is indicated; the short helix visible at the top right of the rotated figure corresponds to 
residues 596-608 at the extreme C-terminal of menin, which were resolved only in PDB 3u84 
chain A. B) As A, but superimposed with the structures of MLL (blue) and PSIP (grey) from 
PDB 3u88. 
Figure 3: Pathogenic variants are predicted to destabilise menin structure. A) In silico 
mutagenesis and thermodynamic analysis for menin variants; for each variant, the average 
change in thermodynamic stability, ∆∆G, was calculated across all structures contained the 
relevant residue, then plotted by variant group; black circles and vertical lines within each 
data area represent median and upper and lower quartiles respectively. Numbering above data 
points shows p values (Student’s Two-tailed t-test) between groups as indicated. B) ∆∆G 
values for benign (blue) and pathogenic (red) variant groups calculated for 31 individual PDB 
structures as shown on the x-axis. C) Average ∆∆G values for benign and pathogenic variants 
occurring at the same amino acid position (residues with one benign and one pathogenic 
variant, n=16; residues with two benign and one pathogenic variants, n=5; residues with one 
benign and two pathogenic variants, n=1); coloured boxes show the range between upper and 
lower quartiles; horizontal lines within each data box show median value; data points are 
shown for outliers only. The difference in the average ∆∆G value between groups was highly 
significant (p=0.0002). 
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Figure 4: Population frequency  of MEN1 variants. The frequency of benign and uncertain 
missense variants in the gnomAD database plotted against ∆∆G value; blue fill: variants 
occurring in the gnomAD database only; yellow fill: variants reported in the gnomAD and 
SGCD databases; grey fill: variants in both gnomAD and HGMD Pro (DM class) databases. 
In cases where different nucleotide substitutions give rise to the same amino acid change, 
frequency is shown as a total for all variant alleles.  
Figure 5: Molecular distribution of pathogenic and benign variants. A) Relative solvent 
accessibility was calculated for each variant group; black circles and vertical lines within 
each data area represent median and upper and lower quartiles respectively. Numbering 
above data points shows p values (Student’s Two-tailed t-test) between groups as indicated. 
B) Buried pathogenic variants are predicted to be the most destabilising to menin structure; 
note that 6/7 of the novel missense variants reported here are deeply buried within the protein 
(RSA < 0.02), while only novel variant H46P is solvent accessible. C, D) Surface distribution 
of solvent-accessible variants. The surface of menin (grey), either alone (C) or in complex 
(D) with KMT2A (yellow) and PSIP (green) shows all variants with RSA>0.2: blue, benign; 
red, pathogenic; purple colouring show positions at which different pathogenic and benign 
variants have been observed; the novel H46P variant is coloured cyan. The broken yellow 
oval indicates a cluster of pathogenic variants which may constitute an as yet unidentified 
interface for protein-protein interactions. E) menin is shown as a grey ribbon; novel missense 
variants are coloured cyan with sidechains displayed in stick format; KMT2A and DSIP are 
shown as in D. 
Figure 6: Effect of protein-protein interaction on ∆∆G. Analysis of solvent accessibility 
and thermodynamic effect of variants was performed on PDB 3u88 (menin:KMT2A:DSIP 
complex), both on menin chains in isolation (chains A, B) and as part of the complex. The 
upper graph shows the average difference in solvent accessibility by position in the 
complexed and isolated menin chains respectively (∆RSA = RSA [complex] – RSA 
[isolated]); the lower graph shows the equivalent difference in average ∆∆G value at each 
position (i.e. ∆∆∆G); data points are labelled for variants where ∆∆∆G 3 kcal/mol; 
background shading indicates positions of menin residues forming contacts with KMT2A 
(yellow) or DSIP (green) in PDB 3u88. 
Figure 7. Predicted thermodynamic stability correlates with observed expression. A) 
Steady-state expression levels have been reported for a number of menin variants; relative 
expression level data was sorted into two groups according to ∆∆G value as calculated in this 
study (neutral or weakly destabilising: ∆∆G <3 kcal/mol [n=14]; strongly destabilising: >3 
kcal/mol [n=27]); boxes show the range between upper and lower quartiles; horizontal lines 
within each data box show median value; data points are shown for outliers only. The 
difference in relative expression between the two groups was highly significant (p=0.0001). 
Figure 8. Using thermodynamic analysis to assess the impact of novel missense variants. 
A) ROC curves for groups of pathogenic and benign variants as functions of ∆∆G value (red 
line; AUC, 0.833), REVEL score (blue line; AUC, 0.864) PolyPhen2 probability for 
pathogenicity (black line; AUC, 0.819) and SIFT score (broken black line; AUC = 0.819); 
open circles on ∆∆G and REVEL traces indicate positions corresponding to threshold values 
of 3 kcal/mol and 0.7 respectively. B) Scatter plot of ∆∆G value against REVEL score for all 
variants (red circles, pathogenic; blue fill, benign; grey fill, uncertain; cyan fill, novel). 
Where different nucleotide substitutions give rise to the same amino acid change, the REVEL 
score was calculated as an average of values for the individual nucleotide variants. Broken 
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horizontal and vertical lines indicate thresholds of ∆∆G = 3 kcal/mol and REVEL score = 0.7 
respectively; note that all 7 novel missense variants cluster in the upper right quadrant of the 
plot. 
 
Table 1: Details of 7 novel missense variants in MEN1. All variants refer to MEN1 
transcript NM_130799.2, protein NP_570711.1 (610 amino acid isoform). 
variant # 1 2 3 4 5 6 7 
HGVS c. notation c.137A>C c.490G>C c.524T>C c.1033G>C c.1078A>T c.1091T>C c.1256G>A 
HGVS p. notation p.(His46Pro) p.(Ala164Pro
) 
p.(Leu175Pro
) 
p.(Ala345Pro
) 
p.(Ile360Phe
) 
p.(Phe364Ser
) 
p.(Gly419As
p) 
genomic variant 
(GRCh37/hg19) 
chr11:64577
445T>G 
chr11:64575
527C>G 
chr11:64575
493A>G 
chr11:64573
720C>G 
chr11:64573
214T>A 
chr11:64573
201A>G 
chr11:64572
600C>T 
reported in 
gnomAD? 
no no no no no no no 
SIFT prediction Damaging Damaging Damaging Damaging Damaging Damaging Damaging 
PROVEAN 
prediction 
Deleterious Deleterious Deleterious Deleterious Deleterious Deleterious Deleterious 
PolyPhen prediction probably 
damaging 
probably 
damaging 
probably 
damaging 
probably 
damaging 
probably 
damaging 
probably 
damaging 
probably 
damaging 
REVEL score 0.894 0.925 0.965 0.909 0.883 0.945 0.912 
Table 2: MEN1 crystal structures used in FoldX analysis. A total of 29 PDB structures 
containing 31 menin chains were used for thermodynamic analysis using FoldX; 7 
representative structures were also used for relative solvent accessibility (RSA) analysis. 
PD
B 
ID 
Title resoluti
on (Å) 
release 
date 
Menin 
chain(
s) 
used for 
RSA 
analysis? 
Refere
nce 
3u8
4 
Crystal structure of Human Menin 2.50 15/02/20
12 
A, B Yes 
(chain A) 
29 
3u8
5 
Crystal structure of human menin in complex with MLL1 (KMT2A) 3.00 15/02/20
12 
A Yes 
3u8
6 
Crystal structure of human menin in complex with JunD 2.84 15/02/20
12 
A   
3u8
8 
Crystal structure of human menin in complex with MLL1 (KMT2A) and 
LEDGF (PSIP) 
3.00 15/02/20
12 
A, B Yes 
(chain B) 
4gp
q 
Structural insights into inhibition of the bivalent menin-MLL interaction 
by small molecules in leukemia 
1.46 19/09/20
12 
A   30 
4gq
3 
Human menin with bound inhibitor MI-2 1.56 19/09/20
12 
A   
4gq
4 
Human menin with bound inhibitor MI-2-2 1.27 19/09/20
12 
A   
4gq
6 
Human menin in complex with MLL (KMT2A) peptide 1.55 19/09/20
12 
A   
4i8
0 
Crystal structure of human menin in complex with a high-affinity 
macrocyclic peptidomimetics 
3.10 06/03/20
13 
A Yes 31 
4og
3 
Human menin with bound inhibitor MIV-3R 2.01 05/03/20
14 
A   32 
4og
4 
Human menin with bound inhibitor MIV-3S 1.45 05/03/20
14 
A   
4og
5 
Human menin with bound inhibitor MIV-5 1.63 05/03/20
14 
A   
4og
6 
Human menin with bound inhibitor MIV-4 1.49 05/03/20
14 
A   
4og
7 
Human menin with bound inhibitor MIV-7 2.08 05/03/20
14 
A   
4og
8 
Human menin with bound inhibitor MIV-6R 1.53 05/03/20
14 
A   
4x5
y 
Menin in complex with MI-503 1.59 15/04/20
15 
A   33 
4x5
z 
Menin in complex with MI-136 1.86 15/04/20
15 
A   
5db
0 
Menin in complex with MI-352 1.50 30/03/20
16 
A   34 
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5db
1 
Menin in complex with MI-336 1.86 30/03/20
16 
A   
5db
2 
Menin in complex with MI-389 1.54 30/03/20
16 
A   
5db
3 
Menin in complex with MI-574 1.71 30/03/20
16 
A   
5dd
9 
Menin in complex with MI-326 1.62 09/09/20
15 
A   35 
5dd
a 
Menin in complex with MI-333 1.83 09/09/20
15 
A Yes 
5dd
b 
Menin in complex with MI-319 1.54 09/09/20
15 
A   
5dd
c 
Menin in complex with MI-2-3 1.62 06/07/20
16 
A   
5dd
d 
Menin in complex with MI-836 2.14 09/09/20
15 
A   
5dd
e 
Menin in complex with MI-859 1.78 09/09/20
15 
A   
5dd
f 
Menin in complex with MI-273 1.66 09/09/20
15 
A Yes 
6b4
1 
Menin bound to M-525 2.61 24/01/20
18 
A Yes 36 
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